

AIDS VACCINE 2010
Satellite symposium
Tuesday, 28 September 2010

**“Exposed uninfected and HIV controllers:
models for preventive and therapeutic vaccines?”**

The Satellite meeting on HIV controllers at the AIDS Vaccine 2009 outlined the relevance of this model for the vaccine research. The Satellite "Exposed uninfected and HIV controllers: models for preventive and therapeutic vaccines? 2010 will broaden the topic to another highly relevant model of protection against HIV infection, the HIV exposed yet uninfected individuals. The main goals of the meeting are: to update our knowledge to the more recent results in the field; to compare and discuss the mechanisms of control of HIV infection in the two models, focusing on innate and adaptive immune responses, to infer new hints potentially useful to drive the research for new vaccine strategies.

Organizers: Gianfranco Pancino and Bruce Walker

Steering committee: Steven Deeks, Michael Lederman, Olivier Lambotte

8.30-8.40 am Welcome and introduction (G. Pancino)

8.40-12: **Session “HIV Controllers”**

Chairs: O. Lambotte and M. Connors

10 min speech + 10 min discussion

Coffee break 20 min

J Coffin, Department of Molecular Biology and Microbiology, Tufts University, Boston, MA 02111, USA.

HIV evolution in Elite and non controllers

E. Haddad, Vaccine & Gene Therapy Institute Florida, Port St. Lucie, Florida, USA

Learning from Controllers; correlates of immunity in HIV infection

PA Goepfert, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
“IL-21 producing CD8 T cells are associated with HIV-1 control”

LA Chakrabarti, Unité d'Immunogénétique Cellulaire, Institut Pasteur, Paris, France

Evidence for a high avidity CD4+ T cell response directed against Gag in HIV Controllers: implications for HIV vaccine design

X Yu, The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, MA 02129. USA

Unique Functional Properties of Myeloid Dendritic Cells in HIV-1 Elite Controllers

JP Herbeuval, Centre Nationale de la Recherche Scientifique, UMR 8147, Université Paris Descartes, Paris, France

Intracytoplasmic sequestration of TRAIL death receptor 5 in CD4+ T cells from HIV controllers

M. Lichterfeld, Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, MA 02129. USA

Elite controllers resist HIV-1 infection via p21 (cip-1/waf-1)

MR Betts, Department of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

CD8+ T cell effector function in progressive and nonprogressive HIV infection

G Alter, Ragon Institute of MGH, MIT, Boston, Massachusetts, USA

ADCC and control of HIV

DI Watkins, Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI 53706

"A macaque model for HIV elite controllers?"

12 - 13 am lunch

13-14.40 pm : **Session "Exposed uninfected individuals"**

Chairs: M. Lederman and F. Plummer GP

10 min speech + 10 min discussion

KR Fowke, Department of Medical Microbiology, University of Manitoba, Canada

Immune Quiescence in the Nairobi Sex Worker Cohort

K Broliden, Department of Medicine, Infectious Disease Unit, Center for Molecular Medicine (CMM)

L8:01, Karolinska University Hospital, Solna, S-17176 Stockholm, Sweden

Innate barriers in the genital tract to HIV infection

MM Addo, Ragon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

T cell immunity in EU: Lessons learned from discordant couples in Zambia

NF Bernard, Division of Clinical Immunology, Research Institute of the McGill University Health Centre, McGill University, Canada.

Natural Killer cells and protection from HIV infection

Coffee break 20 min

15.00-16.20 pm: Open session "HIC and EU relevance for vaccine strategies"

Chairs: Steve Deeks, Michael Lederman

Y. Levy, Hopital Henri Mondor and INSERM U955, Créteil, France

Perspectives in AIDS Vaccine research (10 min speech + 10 min discussion)

Discussion and "wild" presentation of results by the audience.

16.20-16.30 Concluding remarks: B. Walker